Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA
Category
306 releases
Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA
RAISING FULL-YEAR GUIDANCE ACROSS ALL KEY METRICS
Conference Call and Webcast scheduled for tomorrow, November 5, 2026 at 10:00 am MT
Declares Fourth Quarter 2026 Base Dividend of $0.36 Per Share with Supplemental Dividend
Compass Diversified Reports Third Quarter 2026 Financial Results
Sequentially, net sales increased 5.7%, gross profit increased 28.3% and
Narrows FY26 Revenue and Adjusted EBITDA Guidance Ranges with the Midpoints Unchanged, and Reiterates Gross Margin and Free Cash Flow Guidance
AMH (NYSE: AMH) (the "Company"), a leading large-scale integrated owner, operator and developer of single-family rental homes, today announced its…
•Revenue of $195.1 million, up 3% year-over-year, above the midpoint of the Company’s guidance range
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Blue Owl Technology Finance Corp. (NYSE: OTF) ("OTF" or the "Company") today announced financial results for its third quarter ended September 30,…
Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test PreTRM® test…
Ordering healthcare providers increase 34% sequentially and approximately three-fold from 1Q26
Q3 Revenue Growth Accelerates to 31% Y/Y to $198 Million, Driven by Record New Member Acquisition as well as Continued MTM Growth and ARPU Expansion